Lupin’s ESG Score Rises to 76 in S&P Global ESG Ratings

December 03, 2024 01:15 AM AEDT | By Businesswire India

Google News:

Lupin’s ESG Score Rises to 76 in S&P Global ESG Ratings — Image source: Businesswire India

Recent News

Fed Daly eyes fall for possible policy shift

Fifth Third Announces Three-Year, $20M Investment in North Nashville

Inogen Alliance Associate Awards: Environment Analyst Sustainability D...

New Zealand Construction Report 2025: Output to Contract by 1% Due to...

Business Wire India
Global pharma major Lupin Limited (Lupin) today announced its S&P Global ESG scores have moved up to 76 from 69 last year, well above the industry average of 30 in the pharmaceuticals sector. The company has demonstrated consistent and sustained growth in its Environment, Social and Governance (ESG) performance, underlying its commitment to all aspects of business. Lupin’s steady climb in the S&P Global ESG scores is one amongst the fastest in the pharma industry in India.

A strong Sustainability framework is at the heart of Lupin’s strategy and the company has integrated it in all its business operations. By accelerating its transition to net-zero emissions, enhancing social impact, and upholding the highest standards of governance, Lupin is paving the way for a more sustainable and equitable future.

Commenting on the achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin said, “We have made significant progress in our Environmental, Social, and Governance goals over the last four years. The S&P score reaffirms our commitment to prioritizing sustainability and creating impactful and sustainable healthcare solutions that benefit our patients and our communities worldwide.”

Some of Lupin’s main focus areas on the ESG front are environmental stewardship (climate change, water recycling, circular economy, LCA, biodiversity assessment), employee well-being (diversity, equity and inclusion), supply chain sustainability, and patient-centric innovation. The Company has increased its share of use of renewable energy to 33.8% and reduced carbon emissions by 21% over the last year. The company is water positive in all its water usage.

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.